Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc., 6633 [2014-02202]
Download as PDF
<![CDATA[
6633
Federal Register / Vol. 79, No. 23 / Tuesday, February 4, 2014 / Notices
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–02209 Filed 2–3–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Sigma Aldrich Research Biochemicals,
Inc.
Pursuant to 21 CFR 1301.33(a), this is
notice that on November 19, 2013,
Sigma Aldrich Research Biochemicals,
Inc., 1–3 Strathmore Road, Natick,
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following classes of controlled
substances:
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Etorphine HCl (9059) ...................
Methcathinone (1237) ..................
Mephedrone(4-Methyl-Nmethylcathinone) (1248).
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2-Thienyl)cyclohexyl] piperidine (TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
MDPV(3,4Methylenedioxypyrovalerone)
(7535).
VerDate Mar<15>2010
20:14 Feb 03, 2014
I
II
I
I
I
I
I
I
I
I
I
Drug
Schedule
Methylone(3,4-Methylenedioxy-Nmethylcathinone) (7540).
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 7, 2014.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–02202 Filed 2–3–14; 8:45 am]
BILLING CODE 4410–09–P
I
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
I
I
I
I
I
I
I
I
Jkt 232001
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey Pharmaceutical
Materials, Inc.
Pursuant to 21 CFR 1301.33(a), this is
notice that on December 23, 2013,
Johnson Matthey Pharmaceutical
Materials, Inc., Pharmaceutical Service,
25 Patton Road, Devens, Massachusetts
01434, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
Drug
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Nabilone (7379) ............................
Hydrocodone (9193) .....................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Schedule
II
II
II
II
II
II
II
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 7, 2014.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–02208 Filed 2–3–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambridge Isotope Lab
By Notice dated August 15, 2013, and
published in the Federal Register on
August 26, 2013, 78 FR 52802,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 79, Number 23 (Tuesday, February 4, 2014)]
[Notices]
[Page 6633]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-02202]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Sigma Aldrich Research Biochemicals, Inc.
Pursuant to 21 CFR 1301.33(a), this is notice that on November 19,
2013, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road,
Natick, Massachusetts 01760-2447, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Etorphine HCl (9059)....................... II
Methcathinone (1237)....................... I
Mephedrone(4-Methyl-N-methylcathinone) I
(1248).
Aminorex (1585)............................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
1-[1-(2-Thienyl)cyclohexyl] piperidine I
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)............ I
MDPV(3,4-Methylenedioxypyrovalerone) (7535) I
Methylone(3,4-Methylenedioxy-N- I
methylcathinone) (7540).
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Ecgonine (9180)............................ II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 7, 2014.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-02202 Filed 2-3-14; 8:45 am]
BILLING CODE 4410-09-P
